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Abstract
Background: Live attenuated influenza vaccine (LAIV) might increase the risk of wheezing in 
persons with asthma or children younger than 5 years with a history of recurrent wheezing.
Objective: To describe the use and assess the safety of LAIV in persons with asthma in the 
Vaccine Safety Datalink population.
Methods: We identified persons with asthma using diagnosis codes and medication records in 7 
health care organizations over 3 influenza seasons (2008–2009 through 2010–2011) and 
determined their influenza vaccination rates. Using the self-controlled risk interval method, we 
calculated the incidence rate ratio of medically attended respiratory events in the 14 days after 
LAIV compared with 29 to 42 days after vaccination in persons 2 through 49 years old.
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Results: In our population of 6.3 million, asthma prevalence was 5.9%. Of persons with asthma, 
approximately 50% received any influenza vaccine but less than 1% received LAIV. The safety 
study included 12,354 LAIV doses (75% in children; 93% in those with intermittent or mild 
persistent asthma). The incidence rate ratio for inpatient and emergency department visits for 
lower respiratory events (including asthma exacerbation and wheezing) was 0.98 (95% confidence 
interval 0.63–1.51) and the incidence rate ratio for upper respiratory events was 0.94 (95% 
confidence interval 0.48–1.86). The risk of lower respiratory events was similar for intermittent 
and mild persistent asthma, across age groups, and for seasonal trivalent LAIV and 2009 H1N1 
pandemic monovalent LAIV.
Conclusion: LAIV use in asthma was mostly in persons with intermittent or mild persistent 
asthma. LAIV was not associated with an increased risk of medically attended respiratory adverse 
events.
Introduction
Asthma is a risk factor for developing complications from influenza infection.1 Influenza 
vaccine has been recommended for persons with asthma since 1964 in the United States.1 
Inactivated influenza vaccine (IIV) is considered safe for administration to persons with 
asthma.2 Live attenuated influenza vaccine (LAIV) is approved in the United States for 
intranasal administration to individuals 2 to 49 years of age. The US prescribing information 
warns that persons of any age with asthma and children younger than 5 years with recurrent 
wheezing could be at increased risk of wheezing after the administration of LAIV.3 The 
precaution about LAIV use in asthma originated from inadequate study of LAIV in such 
persons.3,4 The precaution in children younger than 5 years with recurrent wheezing 
originated from a pre-licensure clinical trial that observed an increased risk of asthma and 
wheezing in this age group, although the significance of these findings has been questioned.
5,6
The US influenza vaccine recommendations are updated annually based on the most recent 
evidence. During the 2014 to 2015 season, LAIV was preferred over IIV for healthy children 
2 to 8 years old because studies showed LAIV had superior efficacy in this age range.1 This 
stimulated interest in expanding the use of LAIV in children with asthma. However, US 
influenza vaccine effectiveness studies in subsequent seasons found that LAIV was less 
effective than IIV, so the US recommendations were changed to state that LAIV should not 
be used in the 2016 to 2017 season.7 LAIV is still recommended during 2016 to 2017 in 
other countries such as Canada and the United Kingdom.8,9 In Canada and the European 
Union, the asthma-related precaution for LAIV is only for individuals with severe asthma or 
active wheezing.8,10 If a preference for LAIV over IIV is recommended in a future influenza 
season, then interest in using LAIV in asthma in the United States might increase again. 
Even before LAIV was preferentially recommended, some people with asthma and children 
with recurrent wheezing received LAIV. Our objective was to describe the use of LAIV in 
persons with asthma and to assess the safety of this practice.
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Methods
The Vaccine Safety Datalink (VSD) is a collaboration between the Centers for Disease 
Control and Prevention and several integrated health care organizations (sites) in the United 
States that performs vaccine safety research and surveillance.11 Seven sites contributed data 
to this study, which included health care visit diagnoses coded using the International 
Classification of Diseases, Ninth Revision (ICD-9), medication dispensing, and 
immunization records. We studied 3 influenza seasons: 2008 to 2009, 2009 to 2010 (which 
included the seasonal trivalent influenza vaccine and the pandemic influenza A [H1N1] 2009 
monovalent vaccine), and 2010 to 2011. For each season, we retrospectively identified a 
cohort of VSD site members at least 2 years old who were enrolled for more than 91% of the 
days during the 12 months before July 1 (to identify pre-existing asthma) and were enrolled 
continuously from August 31 through April 1 (to have had a chance to receive an influenza 
vaccine). Age was calculated on July 1 of each year.
For persons at least 5 years of age, we defined a case of asthma as anyone who met at least 1 
of the following criteria in the prior 12 months: (1) a diagnosis of asthma (ICD-9 code 
493.xx) for at least 2 clinic visits, or at least 1 emergency department (ED) visit, or at least 1 
hospitalization; (2) at least 2 short-acting β-agonist (SABA) medications dispensed; (3) at 
least 1 SABA and at least 1 other asthma medication dispensed, which included inhaled 
corticosteroids, inhaled long-acting β-agonists, combination inhalers, methylxanthines, mast 
cell stabilizers, leukotriene modifiers, and omalizumab. For children younger than 5 years, 
we defined a case of asthma as anyone who had a diagnosis of asthma (ICD-9 code 493.xx) 
in the prior 12 months for at least 2 clinic visits, or at least 1 ED visit, or at least 1 
hospitalization. We defined a case of recurrent wheezing as a child younger than 5 years 
who had at least 1 of the following criteria in the prior 12 months: (1) at least 2 visits for any 
of the following ICD-9 codes in any setting: acute bronchiolitis (466.1), bronchitis not 
specified as acute or chronic (490), chronic bronchitis (491), other disease of the trachea or 
bronchi (519.1), wheezing (786.07), or other respiratory distress or insufficiency (786.09); 
(2) at least 2 SABA medications dispensed; (3) at least 1 SABA and at least 1 other asthma 
medication dispensed. These definitions were adapted from previous studies.12–14 Patients 
of any age who met only the medication-dispensing criteria were excluded if they had 1 of 
the following diagnoses listed: emphysema (492, 506.4, 518.1, 518.2), chronic obstructive 
pulmonary disease (491.2, 493.2, 496, 506.4), cystic fibrosis (277.0), or acute respiratory 
failure (518.81).15 We assessed asthma severity using criteria developed by Leidy et al,16 
which classify asthma as intermittent or mild, moderate, or severe persistent based on the 
number of SABA and oral corticosteroid medications dispensed during the prior 12 months, 
whereby larger dispensing numbers indicate more severe asthma.
We calculated asthma prevalence as the number of persons with asthma divided by the 
number of persons enrolled in the cohort. For persons with asthma, we calculated IIV and 
LAIV vaccination rates. We assessed the safety of LAIV in persons with asthma 2 to 49 
years of age using the self-controlled risk interval (SCRI) method, which compares the 
incidence of an adverse event in a risk interval after vaccination with the incidence of the 
event in a control in-terval.17 The risk interval is chosen to represent a period during which 
LAIV might affect the outcome of interest, whereas the control interval represents a period 
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during which LAIV should not have a biologically plausible effect on the outcome. 
Comparing 2 different intervals for the same individual inherently controls for factors that 
do not change over time. Choosing a control interval that is relatively short and close in time 
to the risk interval implicitly controls for factors that change over time, such as age and 
season. We used conditional Poisson regression to calculate the incidence rate ratio (IRR) of 
each outcome during the risk interval compared with the control interval using an offset term 
to account for different interval lengths. Each outcome was counted no more than once per 
interval.
The primary outcome of interest was lower respiratory tract events, including asthma 
exacerbation and wheezing. Other outcomes were selected based on findings from previous 
studies and postmarketing reports and included upper respiratory tract events (eg, 
nasopharyngitis and epistaxis), allergic reactions (eg, urticaria), and abdominal pain. 
Outcomes were defined as health care visits associated with selected ICD-9 codes. ED visits 
and inpatient admissions were grouped together because they are more likely to represent 
acute or severe events, whereas clinic visits were analyzed separately. We also evaluated the 
risk of having a post-vaccination health care visit for any reason and searched for any deaths 
within 90 days after vaccination. Subgroup analyses were performed to look for differences 
by age, asthma severity, or vaccine formulation (ie, seasonal trivalent or pandemic 
monovalent). Children younger than 5 years with recurrent wheezing were analyzed 
separately. Patients included in the safety study were continuously enrolled from the date of 
vaccination (defined as day 0) through postvaccination day 42. We excluded patients who 
received more than 1 LAIV dose during a season.
The power for the SCRI method is related to the number of events that occur in vaccinated 
individuals and therefore can be different for each outcome studied depending on how 
common the outcome is.18 Our study had 80% power to detect an IRR of at least 1.3 for 
outcomes with at least 459 total events in the sum of the risk and control intervals when 
using intervals of 14 days each and an α value equal to 0.05 for a 2-sided test. This level of 
risk was detectable for the lower and upper respiratory outcomes in the clinic setting for the 
full cohort. For subgroup analyses and for inpatient and ED outcomes (which were less 
common), the level of detectable risk varied but was generally greater; we had 80% power to 
detect an IRR of at least 1.5 for outcomes with at least 194 total events, an IRR of at least 
2.0 for outcomes with at least 69 total events, and an IRR of at least 3.0 for outcomes with at 
least 29 total events. Analysis was performed using SAS 9.4 (SAS Institute, Cary, North 
Carolina). Institutional review boards at the Centers for Disease Control and Prevention and 
each site approved this study.
Results
Asthma Prevalence
Our study population had more than 6.3 million persons meeting the enrollment criteria in 
each of the 3 influenza seasons studied and overall 5.9% had asthma (Table 1). Of persons at 
least 5 years old for whom our asthma case definition could be met by either diagnosis or 
medication-dispensing criteria, 23% met the diagnosis criteria only, 47% the medication-
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dispensing criteria only, and 30% met both criteria. Asthma severity was classified as 
persistent in 52% of cases (mild in 39%, moderate in 9%, and severe in 4%).
Influenza Vaccination Rates
Approximately 50% of persons with asthma received a seasonal influenza vaccine in each of 
the 3 seasons studied and 28% received a 2009 H1N1 pandemic vaccine (Table 2). Of 
persons with asthma who received an influenza vaccine, 98% received IIV and 2% received 
LAIV. LAIV use was greatest in children 2 to 8 years old and decreased with age. Influenza 
vaccine coverage varied by asthma severity; persons with greater severity were more likely 
to receive an influenza vaccine but were less likely to receive LAIV (Table 3).
LAIV Safety
Of persons with asthma 2 to 49 years old, there were 11,761 unique individuals contributing 
12,354 doses of LAIV to the safety study. These included 8,413 seasonal doses (2,383 in 
2008—2009; 2,414 in 2009–2010; 3,616 in 2010–2011) and 3,941 pandemic doses; 9,294 
doses (75%) were received by children 2 to 17 years old. For all ages, 855 doses (7%) were 
received by persons with moderate or severe persistent asthma.
The risk of having a health care visit for any reason during postvaccination days 1 to 14 was 
not significantly different from the risk during postvaccination days 29 to 42. The number of 
inpatient visits was 25 compared with 41 (IRR 0.61; 95% confidence interval [CI] 0.37–
1.00), the number of ED visits was 118 compared with 92 (IRR 1.28; 95% CI 0.98–1.68), 
and the number of clinic visits was 2,096 compared with 2,072 (IRR 1.01; 95% CI 0.95–1.07).
Three percent of LAIV recipients had clinic visits for lower respiratory outcomes during the 
14 days after vaccination and 0.3% had an inpatient or ED visit. The risk of medically 
attended lower respiratory events was not increased in either setting; findings were similar 
for seasonal and pandemic LAIV formulations and across age groups (Table 4). Asthma 
severity subgroup analyses were well powered for the clinic setting for all severity levels but 
were underpowered for the inpatient and ED setting for the moderate and severe persistent 
asthma subgroups.
Medically attended upper respiratory events, which occurred less frequently than lower 
respiratory events, were not significantly increased after LAIV (Table 5). Upper respiratory 
event subgroup analyses had lower power for the inpatient and ED setting and for the 
moderate and severe persistent severity subgroups in the clinic setting because of the small 
number of events.
Clinic visits with urticaria (ICD-9 code 708.xx) were increased during postvaccination days 
1 to 14 compared with days 29 to 42 (16 vs 4 events; IRR4.0; 95% CI 1.34–12), with cases 
occurring in all age groups. Most patients (81%) with a clinic visit for urticaria during the 
risk interval had only 1 visit (range 1–4), which was similar to patients in the control interval 
(P = .79). There were 1.3 urticaria clinic visits per 1,000 doses. There was no increased risk 
of urticaria in the inpatient and ED setting (IRR 0.50; 95% CI 0.05–5.51). There were no 
visits for abdominal pain during post-vaccination days 1 to 14. There were no deaths from 
any cause within 90 days after vaccination.
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Children Younger Than 5 Years With Recurrent Wheezing
Of children 2 to 4 years old, 5.3% had asthma and an additional 4.5% had a history of 
recurrent wheezing. Children with recurrent wheezing were less likely to receive an 
influenza vaccine (48.3%) than children with asthma (53.5%) but were more likely to 
receive LAIV (5.6% vs 2.9%). The LAIV safety study of those with recurrent wheezing 
included 1,709 seasonal doses and 430 pandemic doses. There were no significantly 
increased risks of lower or upper respiratory adverse events (Table 6). There was no 
increased risk of health care visits for any reason during postvaccination days 1 to 14 
compared with days 29 to 42 (data not shown).
Discussion
In our safety study of persons with asthma who received LAIV, we observed no increased 
risk of medically attended lower respiratory tract adverse events, including asthma 
exacerbation or wheezing, during the 14 days after vaccination. Our safety study population 
consisted mostly of children 2 to 17 years old (n = 9,294 doses) and persons with 
intermittent or mild persistent asthma. Of LAIV recipients with moderate or severe asthma, 
we did not observe an increased risk of lower respiratory adverse events attended in the 
clinic setting; inpatient and ED setting events were not increased either, but the relatively 
small number of LAIV doses and associated events in those 2 severity subgroups made those 
analyses less informative. We also studied children 2 to 4 years old who did not have an 
asthma diagnosis but did have a history of recurrent wheezing (n = 2,139 doses) and found 
no risk of lower respiratory adverse events after LAIV.
Most clinical trials of LAIV have excluded persons with asthma or children with a history of 
wheezing. Our findings are consistent with the few previous studies of LAIV in persons with 
asthma or wheezing, which have focused on children. A randomized placebo-controlled trial 
conducted in 1997 studied 48 children 9 to 17 years old who had stable moderate to severe 
asthma (defined as forced expiratory volume in 1 second < 80% predicted) and did not find 
any difference in spirometric or clinical outcomes between LAIV and placebo.19 An open-
label field trial of LAIV (n = 2,196 doses) conducted from 1998 through 2002 studied 
children 1.5 to 18 years old with a history of intermittent asthma or wheezing and used a risk 
interval design to compare exposed with unexposed person time for the cohort; it found no 
increased risk for medically attended acute respiratory illnesses, including asthma 
exacerbation.20 A randomized study compared LAIV (n = 1,114 children) with IIV during 
the 2002 to 2003 influenza season in children 6 to 17 years of age with a clinical diagnosis 
of asthma; it found no difference in adverse pulmonary outcomes, including asthma 
exacerbations.21 Two randomized trials comparing LAIV with IIV in children 24 to 71 
months old during 2002 to 2003 and 2004 to 2005 did not exclude persons with mild or 
moderate asthma or history of wheezing; post hoc analysis of children with a diagnosis of 
asthma (n = 333 LAIV recipients) found no difference in rates of wheezing.22 A 
manufacturer-funded postmarketing study using the MarketScan claims database that 
compared children 24 to 59 months old with asthma or recurrent wheezing who received 
LAIV (n = 12,323 doses) with those who received IIV over 3 influenza seasons (2007–2008 
through 2009–2010) found that the children who received LAIV appeared to have less 
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severe forms of asthma and did not detect any safety signals.23,24 A cohort study with 4 
weeks of follow-up performed during 2014 through 2015 focused on administration of 
LAIV to persons 2 to 18 years old with egg allergy, which included 445 children with 
physician- diagnosed asthma or recurrent wheeze; these children had no worsening of their 
asthma control test score after vaccination compared with baseline, and the investigators 
concluded that LAIV seemed to be well tolerated in those with well-controlled asthma or 
recurrent wheeze.25 We also studied LAIV in adults with asthma 18 to 49 years old (n = 
3,060 doses), a group with little previous post-licensure information, and found no increased 
risk of lower respiratory adverse events.
We also evaluated several other outcomes. Rhinorrhea and nasal congestion were the most 
commonly reported adverse events after LAIV in clinical trials.3 We found no increased risk 
of medically attended upper respiratory tract adverse events, although risk estimates for 
inpatient and ED events were limited in the adult subgroup by the rarity of events and in the 
moderate and severe persistent severity subgroups by the small number of doses. Urticaria, 
which has been noted in spontaneous postmarketing reports, was the only outcome for which 
we observed a significantly increased risk.3 The incidence of urticaria was low, and most 
cases were in the clinic setting, suggesting that these were not severe events. Severe 
hypersensitivity reactions such as anaphylaxis after vaccination are rare, with no cases 
detected after more than 800,000 doses of LAIV in a previous study.26
The asthma prevalence in our study population (5.9%) was lower than the 8.2% found in the 
United States by the National Health Interview Survey (NHIS) during 2008 through 2010. 
Previous studies have shown that administrative data tend to underestimate physician-
diagnosed asthma.27 The NHIS found influenza vaccine coverage of 39.9% in insured 
persons with asthma at least 2 years of age during 2005 through 2006.28 Coverage in our 
study was higher than in the previous national estimate but still shows room for 
improvement in this high-risk group. We found that persons with greater asthma severity 
were more likely to receive an influenza vaccine but, as expected, were less likely to receive 
LAIV. This also was true during the 2009 H1N1 pandemic, although in the United States 
persons with asthma were one of the priority groups recommended to receive the pandemic 
vaccine first and LAIV was available somewhat sooner than IIV. Our safety findings for the 
2009 H1N1 pandemic LAIV vaccine could help inform recommendations in a future 
pandemic if a similar LAIV formulation were to be available.
This study was subject to several potential limitations. First, the VSD sites might not receive 
records of all influenza vaccine doses received by their members, particularly doses given in 
nontraditional settings.29,30 This could have resulted in an underestimation of influenza 
vaccine coverage in our study, but it would not have biased the SCRI safety study, which 
included only vaccinated individuals. Second, we had to exclude persons from the SCRI 
study who received 2 LAIV doses during the same influenza season because the second 
dose’s risk interval could coincide with the first dose’s control interval. Children younger 
than 9 years are recommended to receive 2 influenza vaccine doses in the same season if 
they have not received any influenza vaccine previously. During the 2009 to 2010 season, 
anyone could have received a seasonal and a pandemic LAIV dose. Third, our safety study 
was of medically attended outcomes; adverse events without a health care visit, such as self-
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treated asthma exacerbations, were not studied. Fourth, we could not measure the level of 
asthma control, which might be an important factor in how well patients with asthma 
tolerate LAIV. Fifth, our study examined the trivalent seasonal formulation of LAIV. 
Quadrivalent LAIV was approved in the United States in 2012 based on 2 trials that found 
its safety and efficacy were similar to those of trivalent LAIV; the 2 trials excluded persons 
with a history of asthma.31 Postmarketing reports of serious respiratory events have not 
increased since the change to quadrivalent LAIV.32
Our findings considered together with the results of previous studies suggest that the 
precaution in the United States about an increased risk of wheezing after LAIV in persons 
with intermittent or mild persistent asthma or children 2 to 4 years old with a history of 
recurrent wheezing might not be warranted. Our study lacked sufficient power to examine 
the risk of serious lower respiratory outcomes in persons with moderate or severe persistent 
asthma because of the low frequency of LAIV use in such patients in practice; larger 
observational studies or a clinical trial might be required to provide definitive safety 
evidence for LAIV use in groups with greater asthma severity.
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Table 1
Asthma Prevalence in the Study Population Averaged Over 3 Years, 2008 Through 2010
Age group (y) Persons with asthma
(person-years), n
Study population
(person-years), n
Prevalence, %
2–4 34,766 656,246 5.3
5–8 83,748 944,339 8.9
9–17 164,299 2,559,576 6.4
18–49 358,239 7,601,158 4.7
≥50 468,175 7,160,770 6.5
All ages 1,109,227 18,922,089 5.9
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